Sector News

Biotech to drive biggest cancer advancements in decades – report

August 10, 2017
Life sciences

A new report on the prospects of immunotherapy treatments has identified smaller, nimble biotechs and early stage companies as the single biggest factor behind the next generation of approaches in development.

The report concludes that the next five years will be the most promising in the fight against cancer with immunotherapies – such as CAR-T and moderating T-Cell approaches, and innate immunity therapies – delivering far better patient outcomes.

The Inside Perspectives: Will Immunotherapy Knock Out Cancer? report, from WuXi AppTec, predicts that over the next 10-years we will see significantly greater breakthroughs as the industry’s understanding of the immune system improves. There are currently more than 130 biotechs working on new therapies – in addition to 20 big pharmas – and it is believed the smaller companies are more aggressively bringing newer innovations to market. In the long run, pharma will undoubtedly absorb the most promising players in an effort to become leaders in combination therapy approaches, which many argue will deliver the best outcomes.

“The current investor frenzy is comparable to that of the genomics industry at the turn of the century,” said Hui Cai, VP of corporate alliances and head of communications at WuXi AppTec. “The experts we speak with argue that a more complete understanding of the genome and promise of clinical data of these transformative modalities will create a golden age for cancer therapy over the next few years.”

The report does, however, identify a number of immediate challenges. For example, CAR-T, although demonstrating good efficacy in blood cancers, has yet to show enough efficacy in solid tumors. Another challenge is how far towards cures for all patients we can get, particularly for patients with late stage metastatic cancer.

The report concludes that immunotherapies are moving cancer from treatment options that simply extend life or improve experience to more effective cures. The cost of newer therapies is also coming into focus; however, this is a positive pressure on companies to produce significant, not just incremental, outcomes for patients.

By George Underwood

Source: Pharma Times

comments closed

Related News

March 31, 2023

Eli Lilly pours $500M more into API manufacturing site under construction in Ireland

Life sciences

The company plans to pour more than $500 million in additional funds into its active pharmaceutical ingredient (API) plant in Raheen, Limerick County, the country’s Industrial Development Agency (IDA) said. The new funding brings the company’s total investment in the site to 927 million euros ($1 billion).

March 31, 2023

‘Stunning’ 4% yearly rise in R&D share has emerging biopharma dominating pipeline

Life sciences

“If in 2005 someone told you that two-thirds of our industry would be driven on the R&D side by emerging biopharma—it would be unthinkable. If one were to project that trend forward, what it would suggest is that we could have a day when we do this talk, say in 2027 or 2028, where 80% of the industry’s pipeline is coming from emerging companies.”

March 31, 2023

Bayer plans to scale back women’s health R&D

Life sciences

The German healthcare and agrochemicals giant told Reuters that in future its pharma pipeline will focus on cardiovascular disease, neurology, rare diseases and immunology, while de-emphasizing women’s health, a field it first focused on with the acquisition of the former women’s health specialist Schering in 2006.

How can we help you?

We're easy to reach